Home > Reports > Continuous Glucose Monitoring Systems Market Size, Share and Forecast to 2030

Continuous Glucose Monitoring Systems Market

Continuous Glucose Monitoring Systems Market: Information by Component (Sensors, Transmitter, Receiver), End-Use (Hospitals, Home Healthcare), and Region — Forecast till 2030

Published On : 27 Aug, 2020
Updated On : 28 Sep, 2022
Table of Content Download Sample

Market Snapshot

Base Year:
Study Period:
10.2 %
Fastest Growing Market:
Largest Market:
North America

Market Overview

The global continuous glucose monitoring systems market size was valued at USD 5.26 billion in 2021 and is projected to reach USD 12.61 billion by 2030, registering a CAGR of 10.2% from 2022 to 2030.

Continuous Glucose Monitoring (CGM) is one of the newest advanced technologies in diabetes management market landscape. CGM system is a type of glucose monitoring device that uses a transcutaneous or subcutaneous route to insert a biosensor, which measures the levels of glucose in interstitial fluid or blood. These systems play an integral role in diabetes management due to several advantages associated with them over other glucose monitoring devices. Unlike conventional glucose monitors, these systems allow periodic monitoring of glucose levels, which is essential to avoid diabetic complications.

CGMS technology has set up a roadmap for the most-awaited, high-tech, closed-loop artificial/bionic pancreas. Therefore, the development of novel and technically sophisticated CGMS is the primary focus of glucose monitoring device manufacturing companies. It offers a wide array of applications for all age-cohorts, healthcare settings (diagnostic centers/clinics, hospital ICUs, and home healthcare), and across all geographies. Therefore, the market for continuous glucose monitoring systems offers lucrative opportunities for both producers of CGMS and manufacturers of insulin pumps.

Continuous Glucose Monitoring Systems Market Share

Get more information on this report Download Sample Report

Market Dynamics

Growing Prevalence of Diabetes and Rapid Development in Continuous Glucose Monitoring Systems 

Diabetes is a chronic disease, which occurs when the pancreas does not produce adequate insulin or when the body cannot effectively use the produced insulin. As per the World Health Organization (WHO), in 2016, an estimated 422 million adults suffered from diabetes across the globe. The dramatic increase in type 2 diabetes is mainly attributed to the rising incidences of obesity. Some of the common risk factors associated with diabetes include obesity and high blood pressure and cholesterol. As per the Centers for Disease Control and Prevention (CDC) indicate diabetes as the seventh leading cause of death in the U.S. Similarly, as per the International Diabetes Federation, the global diabetes population is estimated to reach 700 million by 2045 from 463 million in 2019.

CGM plays an important role in diabetes management as it offers early detection due to which the risks associated with diabetes, such as heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage, can be avoided.  CGM devices are minimally invasive and provide a simple and effective approach to manage diabetes. They can also detect significant changes in blood glucose levels and aid in preventing hypoglycemic conditions. These devices enable analysis of blood glucose levels at different time intervals with the help of a sensor. The readings generated are processed into diabetes management software through a wireless network that allows patients to understand the disease better.

In May 2015, Medtronic launched the MiniMed 640G System to expand its presence in the continuous glucose monitoring systems market. The system automatically detects low blood glucose levels below defined range and suspends insulin delivery and closely mimics the way healthy pancreas deliver insulin to the body. CGM uses a sensor that connects to MiniMed® insulin pump, giving early warnings about high and low blood glucose levels. Similarly, in 2016, Dexcom G5 Mobile CGM system by Dexcom, Inc. received approval from Health Canada. The system gives real-time glucose readings for patients with type 1 or type 2 diabetes every five minutes.

Innovative Product Launches by Leading Players to Drive the Market Growth

Continuous glucose monitoring system requires fewer accessories and allows for quick data transfer and sharing from the device for further analysis. For instance, DiaMonTech GmbH, a medical device company based in Germany, developed a glucose monitoring system, DMT Pocket, which tests blood glucose non-invasively without drawing blood, pricking the finger, or test strip. It measures the blood glucose level merely by relaxing patient’s fingertip on the sensor and displays the blood glucose levels in 5 to 15 seconds. This device can also communicate with mobile phones at any time, allowing easy access to physiological information.

In June 2018, Senseonics obtained the FDA approval for the Implantable Eversense Continuous Glucose Monitoring (CGM) system in the U.S. The system continuously monitor blood glucose levels for 90 days without the use of lancets; thus, significantly increasing patient convenience.

Segment Analysis

Sensor: A Sophisticated Part of the CGM Device

Based on the component, the continuous glucose monitoring systems market is segmented into transmitter, receiver, and sensor. The sensor segment holds the largest market share on account of rapid technological advancements to improve the accuracy of these sensors. Sensor is the most sophisticated part of the CGM device as it aids in detecting blood glucose levels. These sensors use glucose oxidase that converts glucose to hydrogen peroxidase and reacts with the platinum inside the sensor, generating an electrical signal to be communicated to the transmitter.

Efficient and Easy Monitoring of Blood Glucose Level to Drive the Demand for CGM

Based on end-use, the market is segmented into hospitals, homecare settings, and others such as clinical laboratories and diagnostic centers. The homecare settings segment dominates the global market as these devices enable patients to optimize the intake of insulin doses and facilitates continuous monitoring of blood glucose levels. Homecare settings are expected to increase the demand for CGM devices owing to efficient and easy monitoring of blood glucose levels.

Impact of COVID-19

 Perhaps one of the most significant impacts to occur on the market due to the COVID 19 is a sudden increase in the adoption of CGM systems. Patients suffering from diabetes and physicians recognize the necessity of these devices to address the increased treatment demand and prevent unnecessary complications associated with diabetes, further driving the market growth.  

Regional Overview


Regional Growth Insights Request Sample Pages

Increasing FDA Approval and Government Efforts to Manage the Disease Drives North America’s Market Growth

North America dominates the continuous monitoring systems market as the region houses a huge patient pool suffering from diabetes. As per the International Diabetes Federation, around 48 million people in North America suffered from diabetes in 2019, and the number is projected to reach 63 million by 2045. As per the Centers for Disease Control and Prevention (CDC), in 2015, an estimated 23.1 million people or 7.2% of the U.S. population had diabetes, which included 132,000 children and adolescents younger than the age of 18.

Surging cases of diabetes, efforts undertaken by the government to manage the disease at a broader level, and increasing FDA approval and product launches bolster the market growth. In December 2017, Companion Medical launched the first FDA approved smart insulin pen system in the U.S., INPEN. Apart from this, technological advancement and substantial research and innovation in diabetes care in countries like the U.S. and Canada provide an impetus to the regional market growth.

Asia-Pacific: Home to World’s Highest Diabetic Population

Asia-Pacific is expected to grow with the highest CAGR in the continuous glucose monitoring systems during the forecast period. As per the Asian Diabetes Prevention Initiative, globally, about 60% of the diabetic population resides in the Asia-Pacific region. High prevalence of diabetes in developing countries such as India and China prompts the need for effective glucose monitoring systems.

Rising healthcare expenditure, increasing investment by companies, and favorable regulatory policies bolster the market growth. For instance, in 2017, Novo Nordisk launched the ‘Changing Diabetes’ campaign in China, along with the local Health Care Community, and also donated USD 0.284 million(2 million Yuan) for the betterment of diabetic patients. Similarly, in 2016, the government of Australia subsidized CGM technology to assist young adults and children under the age of 21 suffering from type 1 diabetes. The country is now providing access to subsidized CGM products through the National Diabetes Service Schemes (NDSS).

Key Players

  • Pfizer Inc.
  • Baxter International Inc.
  • Senseonics
  • Dexcom, Inc.
  • Abbott Laboratories
  • Nemaura Medical, Inc
  • Medtronic, Inc.
  • Medtrum Technologies, Inc.
  • Animas Corporation
  • Tandem Diabetes Care
  • Novo Nordisk
  • Ypsomed
  • GlySens

Recent Developments

  • In September 2019, Novo Nordisk collaborated with Medtronic Plc to integrate insulin dosing data from Novo smart insulin pens into CGM devices. This collaboration will help both patients and healthcare professionals to view glucose and insulin data together on the CGM display.
  • In January 2019, Medtronic Plc signed a collaboration agreement with Eris Life sciences to develop a smart continuous glucose monitoring system, Guardian Connect. 

Continuous Glucose Monitoring Systems Market Segmentation

By Component

  • Transmitters
  • Receivers
  • Sensors

By End-Use

  • Hospitals
  • Homecare Settings

By Region

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • The Middle East and Africa

Frequently Asked Questions (FAQs)

In 2019 Global Continuous Glucose Monitoring Systems Market was valued at USD 1,965.2 million.
Growing prevalence of diabetes and rapid development in continuous glucose monitoring systems are the key factors expected to drive Continuous Glucose Monitoring Systems Market during the forecast period.
North America is expected to hold the highest market share in Continuous Glucose Monitoring Systems Market.
Pfizer Inc., Baxter International Inc., Senseonics, Dexcom, Inc., Abbott Laboratories, Nemaura Medical, Inc, Medtronic, Inc., Medtrum Technologies, Inc., Animas Corporation are the top players in Continuous Glucose Monitoring Systems Market.
The global continuous glucose monitoring systems market size is projected to reach USD 12.61 billion by 2030, registering a CAGR of 10.2% from 2022 to 2030.
Sensors Component Segment is expected to be the leading segment in Continuous Glucose Monitoring Systems Market during the forecast period.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times and included in every purchase.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.
Report Metric Details
Market Size USD in Billion By 2030
Historical Data 2019-2020
Base Year 2021
Forecast Period 2022-2030
Forecast Units Value (USD Million)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered by Component (Sensors, Transmitter, Receiver), End-Use (Hospitals, Home Healthcare)
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors Pfizer Inc., Baxter International Inc., Senseonics, Dexcom, Inc., Abbott Laboratories, Nemaura Medical, Inc, Medtronic, Inc., Medtrum Technologies, Inc., Animas Corporation, Tandem Diabetes Care, Novo Nordisk, Ypsomed, GlySens
Key Market Opportunities Rising Demand For Continuous Glucose Monitoring Systems In Healthcare It Industry
Price Starts From

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report